Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Drugs Improve Range of Options for Osteoporosis: 3
March 7, 2011
- PIII Results for Afinitor Published in NEJM
March 7, 2011
- Korosho Approves Norspan, NorLevo after One-Month Delay
March 7, 2011
- Avastin Prolongs PFS in Ovarian Cancer
March 7, 2011
- Nesina Approved for Coadministration with SU and BG: Takeda
March 7, 2011
- JAMS Announces GLs for COI Management
March 7, 2011
- Xeloda Approved for Advanced/Recurrent Stomach Cancer: Chugai
March 7, 2011
- 8 Companies to Withdraw Generic Versions of Dasen
March 7, 2011
- GSK Starts Multinational PIII Study for DMD
February 28, 2011
- Pfizer to Stress Significance of Combining CCB, Statin in One Drug
February 28, 2011
- Increasing Number of Trials Conducted on Concurrent Use of Oral Hypoglycemic Agents
February 28, 2011
- Mylan Aims to Become Top-3 Generic Company in Japan in 5 Years
February 28, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Lixisenatide Not Inferior to Exenatide in PIII: sanofi-aventis
February 28, 2011
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Otsuka HD to Establish Otsuka Medical Devices
February 28, 2011
- Cooperation beyond National Boundaries Necessary in Asia: JPMA President Hasegawa
February 28, 2011
- Takara Bio to Create Research Reagent Joint Venture in India
February 28, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…